Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03703167
Title Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center

central nervous system lymphoma

diffuse large B-cell lymphoma


Ibrutinib + Lenalidomide + Rituximab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.